Assessment of addiction severity among ritual users of ayahuasca

Brasiliano, 2006, A influência da comorbidade com transtornos alimentares na apresentação de mulheres dependentes de substâncias psicoativas, Rev. Psiq. Clín., 33, 134, 10.1590/S0101-60832006000300003 Bullis, 2008, The “vine of the soul” vs. the Controlled Substances Act: implications of the hoasca case, J. Psychoactive Drugs, 40, 193, 10.1080/02791072.2008.10400630 Camí, 2003, Drug addiction, N. Engl. J. Med., 349, 975, 10.1056/NEJMra023160 Carise, 2005 Da Silveira, 2005, Ayahuasca in adolescence: a preliminary psychiatric assessment, J. Psychoactive Drugs, 37, 129, 10.1080/02791072.2005.10399792 Doering-Silveira, 2005, Ayahuasca in adolescence: a neuropsychological assessment, J. Psychoactive Drugs, 37, 123, 10.1080/02791072.2005.10399791 1972 Gable, 2007, Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids, Addiction, 102, 24, 10.1111/j.1360-0443.2006.01652.x Grob, 1996, Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil, J. Nerv. Ment. Dis., 184, 86, 10.1097/00005053-199602000-00004 Halpern, 2008, Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament, Med. Sci. Monit., 14, SR15 Instituto Nacional de Cultura, Perú, 2008. Declaración Patrimonio Cultural de la nación a los conocimientos y usos tradicionales del Ayahuasca practicados por comunidades nativas amazónicas, Resolución Directoral Nacional n° 836. Labate, B.C., Araújo, W.S. (Eds.), 2004. O uso ritual da ayahuasca. Campinas, Mercado de Letras. MacRae, 1998 Mathias, 2009, Differences in addiction severity between social and probable pathological gamblers among substance abusers in treatment in Rio de Janeiro, Int. J. Ment. Health Addict., 7, 239, 10.1007/s11469-008-9183-z McKenna, 2004, Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges, Pharmacol. Ther., 102, 111, 10.1016/j.pharmthera.2004.03.002 McLellan, 1992, The Fifth Edition of the Addiction Severity Index, J. Subst. Abuse Treat., 9, 199, 10.1016/0740-5472(92)90062-S McLellan, 2006, The Addiction Severity Index at 25: origins, contributions and transitions, Am. J. Addict., 15, 113, 10.1080/10550490500528316 Nichols, 2004, Hallucinogens, Pharmacol. Ther., 101, 131, 10.1016/j.pharmthera.2003.11.002 Passie, 2008, The pharmacology of lysergic acid diethylamide: a review, CNS Neurosci. Ther., 14, 295, 10.1111/j.1755-5949.2008.00059.x Pechansky, 2003, Preliminary estimates of human immunodeficiency virus prevalence and incidence among cocaine abusers of Porto Alegre, Brazil, J. Urban Health, 80, 115, 10.1093/jurban/jtg115 Riba, J., 2003. Human pharmacology of ayahuasca. Doctoral Thesis. Barcelona, Universitat Autònoma de Barcelona. http://www.tesisenxarxa.net/TDX-0701104-165104/. Riba, 2003, Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics, J. Pharmacol. Exp. Ther., 306, 73, 10.1124/jpet.103.049882 Riba, 2006, Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant, Psychopharmacology (Berl.), 186, 93, 10.1007/s00213-006-0358-7 1979 Tupper, 2008, The globalization of ayahuasca: harm reduction or benefit maximization?, Int. J. Drug Policy, 19, 297, 10.1016/j.drugpo.2006.11.001 US Supreme Court, no. 04-1084. Gonzales, V., decided 21 February 2006. Centro Espirita Beneficente Uniao Do Vegetal 546 US 2006. Vollenweider, 1999, 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—a PET study with [11C]raclopride, Neuropsychopharmacology, 20, 424, 10.1016/S0893-133X(98)00108-0